1-3 of 3
Marco DiBonaventura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6727.
https://doi.org/10.1182/blood-2023-180984
Published: 2023
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6716.
https://doi.org/10.1182/blood-2023-180848
Published: 2023
Journal Articles

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Shreekant Parasuraman, PhD, Marco DiBonaventura, PhD, Kelly Reith, MS,MBA, Kristen Concialdi, BA
Journal: Blood
Blood (2014) 124 (21): 1852.
https://doi.org/10.1182/blood.V124.21.1852.1852
Published: 2014